1Zhou J, Chen Y, Ying L, et al. Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy[J]. Brae Nephrol, 2014, 15(1) :147-147.
2Gen YC, Dong WL, Na Z, et al. Clinical and prognostic implica- tions of serum uric acid levels on IgA nephropathy:a cohort study of 348 eases with a mean 5-year follow-up[J]. Clin Nephrol, 2013, 80(1) :40-46.
3Iwao O. Relationship between hyperurieemia and chronic kidney disease[J]. Nucleosides Nucleotides & Nucleic Acids, 2011, 30 (12):1 039-1 044.
4Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperurieemia in IgA nephropathy:a retrospective cohort study and randomized controlled trial[J]. Kidney & Blood Pressure Research, 2012, 35 (3) :153-160.
5Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease[J]. Am J Nephrol, 2011, 33(4) : 298-304.
6Bakan A, Oral A, Elcioglu OC, et al. Hyperuricemia is associated with progression of IgA nephropathy[J]. Int Urol Nephrol, 2015, 47(4):673-678.
7Yui-Pong S, Kay-Tai L, Matthew Ka-Hang T, et al. Use of al- lopurinol in slowing the progression of renal disease through its a- bility to lower serum uric acid level[J]. Am J Kidney Dis, 2006, 47(1):51-59.
8Pal BH,Swarnalatha G, Ram R, et al. Allopurinol for prevention of progression of kidney disease with hyperuricemia[J]. Indian J Nephrol, 2013, 23(4) :280-286.
9Goicoechea M, de Vinuesa SG, Verdalles U, et aL Effect of allo- purinol in chronic kidney disease progression and cardiovascular risk[J]. Clin J Am Soc Nephrol, 2010, 5(8) :1 388-1 393.
10Liu WC, Hung CC, Chen SC, et al. Association of hyperurice- mia with renal outcomes, cardiovascular disease, and mortality [J]. Clin J Am Soc Nephrol, 2012, 7(4):541-548.
